研究目的
To evaluate the potential value of the new synthetic drug Caba-780 in the diagnosis and treatment of castration-resistant prostate cancer (CRPC).
研究成果
The new synthetic drug Caba-780 can be efficiently taken up by CRPC cells, exhibits a strong cytotoxic effect, inhibits migration and invasion, promotes apoptosis, and can be used for tumor imaging and growth inhibition in vivo, showing potential applications in the diagnosis and treatment of CRPC.
研究不足
The mechanism by which Caba-780 is metabolized in the cells and its long-term safety need further clarification. The study also did not fully explore the metabolic pathways of Caba-780 in vivo.
1：Experimental Design and Method Selection
The study involved the synthesis of Caba-780 and its evaluation in CRPC cell lines DU145 and PC-3, and the normal human prostate stromal cell line WPMY-1. The uptake, cytotoxicity, migration, invasion, apoptosis, and cell cycle effects of Caba-780 were assessed in vitro. In vivo, the distribution, antitumor effect, and safety of Caba-780 were evaluated in tumor-bearing mouse xenograft models.
2：Sample Selection and Data Sources
CRPC cell lines DU145 and PC-3, and the normal human prostate stromal cell line WPMY-1 were used. Tumor-bearing mouse xenograft models were established for in vivo studies.
3：List of Experimental Equipment and Materials
Confocal laser microscope (Olympus FV1000), microplate reader (Sunrise, TECAN), IVIS Lumina II imaging station (Caliper Life Sciences), and various chemical reagents including Caba-780, IR-780, and cabazitaxel.
4：Experimental Procedures and Operational Workflow
In vitro studies included uptake assays, cytotoxicity assays, migration and invasion assays, apoptosis assays, and cell cycle assays. In vivo studies included tumor imaging and antitumor assays in tumor-bearing mice.
5：Data Analysis Methods
Statistical analysis was performed using SPSS software. A variance test (one-way ANOVA) was used to compare differences between groups.
独家科研数据包，助您复现前沿成果，加速创新突破
获取完整内容
